Gan & Lee Pharmaceuticals
SSE:603087
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
33.1
59.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Gan & Lee Pharmaceuticals stock under the Base Case scenario is 45.32 CNY. Compared to the current market price of 44.65 CNY, Gan & Lee Pharmaceuticals is Undervalued by 1%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Gan & Lee Pharmaceuticals
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Gan & Lee Pharmaceuticals cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Gan & Lee Pharmaceuticals
Balance Sheet Decomposition
Gan & Lee Pharmaceuticals
Current Assets | 6.3B |
Cash & Short-Term Investments | 2B |
Receivables | 394.6m |
Other Current Assets | 4B |
Non-Current Assets | 5.6B |
Long-Term Investments | 439.7m |
PP&E | 3.9B |
Intangibles | 1.1B |
Other Non-Current Assets | 177.1m |
Current Liabilities | 763.7m |
Accounts Payable | 96.3m |
Accrued Liabilities | 137.3m |
Other Current Liabilities | 530.1m |
Non-Current Liabilities | 211.8m |
Long-Term Debt | 3.8m |
Other Non-Current Liabilities | 208m |
Earnings Waterfall
Gan & Lee Pharmaceuticals
Revenue
|
2.7B
CNY
|
Cost of Revenue
|
-750.1m
CNY
|
Gross Profit
|
1.9B
CNY
|
Operating Expenses
|
-1.7B
CNY
|
Operating Income
|
213.5m
CNY
|
Other Expenses
|
291.3m
CNY
|
Net Income
|
504.8m
CNY
|
Free Cash Flow Analysis
Gan & Lee Pharmaceuticals
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Gan & Lee Pharmaceuticals's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Gan & Lee Pharmaceuticals's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Gan & Lee Pharmaceuticals's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Gan & Lee Pharmaceuticals's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Gan & Lee Pharmaceuticals
According to Wall Street analysts, the average 1-year price target for Gan & Lee Pharmaceuticals is 69.36 CNY with a low forecast of 68.68 CNY and a high forecast of 71.4 CNY.
Dividends
Current shareholder yield for Gan & Lee Pharmaceuticals is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Gan & Lee Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of recombinant insulin analogue raw materials and injections. The company is headquartered in Beijing, Beijing and currently employs 3,278 full-time employees. The company went IPO on 2020-06-29. The firm's main products are insulin preparations and insulin dry powder, including Changxiulin recombinant insulin glargine injection and Suxiulin recombinant insulin lispro injection. The company is also involved in the development and sales of a type of insulin pen called Xiulin Pen and the components. The firm provides early-stage franchising services by authorizing other companies to sell its insulin injections. The firm sells its products to both domestic and international markets, including Mexico and the Middle East.
Contact
IPO
Employees
Officers
The intrinsic value of one Gan & Lee Pharmaceuticals stock under the Base Case scenario is 45.32 CNY.
Compared to the current market price of 44.65 CNY, Gan & Lee Pharmaceuticals is Undervalued by 1%.